Search Videos and More
Video
Hodgkin Lymphoma
Ann LaCasce, MD, MMSc, discusses Hodgkin lymphoma and how to approach the different types of Hodgkin patients.
Video
CAR-T Cell Therapy for Lymphoma: Updates and Progress
Caron Jacobson, MD, MMSc, gives updates and shares progress with CAR-T cell therapy for lymphoma.
Symposium
Hematologic Malignancies CME: 2021
The care of patients with hematologic malignancies is evolving rapidly. These video highlights discuss new developments in the diagnosis and treatment of hematologic malignancies presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).
Video
Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.
News
ASH 2021 Highlights - CME
Register for 2021 ASH Highlights CME
Video
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
Dana-Farber Cancer Institute research shows elevated rates of a blood cancer precursor condition in groups at high risk for multiple myeloma.
Video
Blood Cancer Research: Clinical trial helps younger patient
Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.
Video
COVID-19 vaccine and blood cancer
Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.
Video
Blood Cancer: Higher rates of precursor in high-risk individuals
Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.
News
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years
A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
News
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma
Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.
News
American Society of Hematology (ASH) Annual Meeting
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia